A practical reference on FSFI endpoint: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
In 1970, she began research at the Indian Institute of Technology, Kanpur (IIT Kanpur). In that year, she married Subramania Ranganathan, with whom she would go on to author Challenging problems in organic reaction mechanisms (1972), Art in biosynthesis: the synthetic chemist's challenge (1976), and Further challenging problems in organic reaction mechanisms (1980)—as well as editing an ongoing series titled "Current Organic Chemistry Highlights". She continued her research at IIT Kanpur on the basis of fellowships. Unwritten rules prevented her from joining the faculty because her husband was already a member. She began work at Regional Research Laboratory, Trivandrum in 1993, and at IICT, Hyderabad in 1998., where she became Deputy Director. During these years, she conducted ongoing collaborations with Isabella Karle at the U.S. Naval Research Laboratory. Darshan Ranganathan was diagnosed with breast cancer in 1997, and died on her 60th birthday, in 2001. The biennial "Professor Darshan Ranganathan Memorial Lecture", which is to be "delivered by a woman scientist who has made outstanding contributions in any field of Science and Technology" was established in her memory by her husband, in 2001.
=== Japan === One fatal poisoning caused by intravenous injection of a "bath salt" product containing acetylfentanyl mixed with 4'-Methoxy-α-pyrrolidinopentiophenone (a substituted cathinone) has been reported in 2016.
An ex vivo histological examination showed that certain pore geometry and the pre-growing of chondrocytes (Cho) prior to implantation significantly improves the performance of the created 3D scaffolds. The achieved biocompatibility was comparable to the commercially available collagen membranes. The successful outcome of this study supports the idea that hexagonal-pore-shaped hybrid organic-inorganic micro-structured scaffolds in combination with Cho seeding may be successfully implemented for cartilage tissue engineering. Recently, tissue engineering has advanced with a focus on vascularization. Using Two-Photon Polymerization-based additive manufacturing, synthetic 3D microvessel networks are created from tubular hydrogel structures. These networks can perfuse tissues several cubic millimeters in size, enabling long-term viability and cell growth in vitro. This innovation marks a significant step forward in tissue engineering, facilitating the development of complex human tissue models.
Sources: en.wikipedia.org
A mass-selecting quadrupole and collision quadrupole with time-of-flight device as the second mass selection stage is a hybrid known as a quadrupole time-of-flight mass spectrometer (QTOF MS). Quadrupole-quadrupole-time-of-flight (QqTOF) configurations are also possible and used especially the mass spectrometry of peptides and other large biological polymers. A variant of the quadrupole mass analyzer called the monopole was invented by von Zahn which operates with two electrodes and generates one quarter of the quadrupole field. It has one circular electrode and one V-shaped electrode. The performance is, however, lower than that of a quadrupole mass analyzer. An enhancement to the performance of the quadrupole mass analyzer has been demonstrated to occur when a magnetic field is applied to the instrument. Manifold improvements in resolution and sensitivity have been reported for a magnetic field applied in various orientations to a QMS.
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new antihistamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation" and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better-stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg in surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterward. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders.
14 November Archaeologists report the oldest likely evidence (via heated fish teeth from a deep cave) of controlled use of fire to cook food by archaic humans ~780,000 years ago. After being linked to risks for obesity, mental disorders, and potentially other health issues, a study finds a likely association between (contemporary types of) outdoor artificial light at night and diabetes. 15 November A scientific review finds that human sperm counts fell by 62% in the last 50 years and are decreasing at an accelerating rate, likely a result of factors such as poor diets, endocrine disruptors in prevalent products, unhealthy lifestyles and toxic forever chemicals in air and water. A study using neuroimaging identifies rapid GABA boosting as a major potential explanation-component for why learning is often more efficient in children. Scientists report leprosy-causing bacteria viably regenerate and rejuvenate the liver in its armadillos hosts, which may enable novel human therapies. 16 November NASA conducts the first uncrewed flight of its Space Launch System (SLS), the largest rocket in history. The onboard Orion capsule will orbit the Moon before returning to Earth, as a demonstration of planned human missions. A satellite-free GPS-alternative higher-resolution positioning system using existing telecommunications networks is demonstrated, SuperGPS.
===== Iron export ===== Iron export occurs in a variety of cell types, including neurons, red blood cells, macrophages and enterocytes. The latter two are especially important since systemic iron levels depend upon them. There is only one known iron exporter, ferroportin. It transports ferrous iron out of the cell, generally aided by ceruloplasmin and/or hephaestin (mostly in enterocytes), which oxidize iron to its ferric state so it can bind ferritin in the extracellular medium. Hepcidin causes the internalization of ferroportin, decreasing iron export. Besides, hepcidin seems to downregulate both TFR1 and DMT1 through an unknown mechanism. Another player assisting ferroportin in effecting cellular iron export is GAPDH. A specific post translationally modified isoform of GAPDH is recruited to the surface of iron loaded cells where it recruits apo-transferrin in close proximity to ferroportin so as to rapidly chelate the iron extruded. The expression of hepcidin, which only occurs in certain cell types such as hepatocytes, is tightly controlled at the transcriptional level and it represents the link between cellular and systemic iron homeostasis due to hepcidin's role as "gatekeeper" of iron release from enterocytes into the rest of the body. Erythroblasts produce erythroferrone, a hormone which inhibits hepcidin and so increases the availability of iron needed for hemoglobin synthesis.
Sources: en.wikipedia.org
=== Location === Tarlov cysts are most commonly located in the S1 to S4/S5 region of the spinal canal, but can be found along any region of the spine. Tarlov cysts typically form on the extradural portions of the sacral nerve roots, most often near the dorsal root ganglion of the dorsal (sensory) nerve roots. They arise within the perineural space, between the endoneurium and perineurium. Occasionally, these cysts are observed in the lumbar and thoracic spine. The cysts are often multiple, extending around the circumference of the nerve, and can enlarge over time to compress neighboring nerve roots, to cause bone erosion. The cysts may also form on the anterior (front) side of the sacrum and have been known to extend into the pelvic cavity. These cysts, though rare, can be found to grow large - over 3–4 centimetres (1.2–1.6 in) in size, often causing severe pelvic pain from compression on the cyst itself as well as adjoining nerves.
==== Other drugs ==== Alpiropride (Revistel, Rivistel, Rivestel) – dopamine D2 receptor antagonist – migraine Dimetotiazine (Banistyl, Normelin) – non-selective monoamine receptor modulator – migraine Flumedroxone acetate (Demigran, Leomigran) – progestogen (progesterone receptor agonist) – migraine Iprazochrome (Divascan) – serotonin receptor antagonist – migraine Lasmiditan (COL-144; LY-573144; Rayvow; Reyvow) – serotonin 5-HT1F receptor agonist – migraine [141] Lomerizine (DE-090; KB-2796; Migsis) – non-selective monoamine receptor modulator, other actions – migraine [142] Onabotulinum toxin A (BoNTA; Botox; GSK-1358820; OnabotA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [143] Oxetorone (Nocertone, Oxedix) – non-selective monoamine receptor modulator – migraine Topiramate (Epitomax; KW-6485; MCN-4853; RWJ-17021; Topamax; Topimax; Topina) – various actions – migraine [144] Topiramate oral (Eprontia; ET-101) – various actions – migraine [145] Topiramate extended-release (SPN-538; TPM XR; Trokendi XR; Trokesa) – various actions – migraine [146] Valproate semisodium (Depakote; Divalproex; Divalproex sodium; Epival; LA40220) – various actions – migraine [147]
==== Imaging ==== Ultrasound of the thyroid may be used to reveal whether structures are solid or filled with fluid, helping to differentiate between nodules and goitres and cysts. It may also help differentiate between malignant and benign lesions. When further imaging is required, a radiolabelled iodine-123 or technetium-99 uptake scan may take place. This can determine the size and shape of lesions, reveal whether nodules or goitres are metabolically active, and reveal and monitor sites of thyroid disease or cancer deposits outside the thyroid. A fine needle aspiration of a sample of thyroid tissue may be taken in order to evaluate a lesion seen on ultrasound which is then sent for histopathology and cytology. Computed tomography of the thyroid plays an important role in the evaluation of thyroid cancer. CT scans often incidentally find thyroid abnormalities, and thereby practically becomes the first investigation modality.
The successes of Josip Broz Tito's Yugoslav partisans in Dalmatia led the Allies to despatch small patrols into Yugoslavia and Albania to contact partisan leaders and arrange co-operation with the Allied air forces. Several Rhodesian patrols from the LRDG were selected to undertake such missions during August and September 1944. Yugoslav partisans subsequently indicated targets for Allied bombing missions, with some success. From September, members of the LRDG's Rhodesian squadron under Captain Olivey undertook advanced reconnaissance in the Peloponnese peninsula of southern Greece. Landing at Katakolo, they made their way inland to Corinth and, along with the British 4th Parachute Battalion, entered Athens as the Germans departed in November. The Rhodesians of the LRDG spent November and December helping Greek forces to garrison an Athens orphanage against supporters of the communist Greek People's Liberation Army. Four Rhodesians were killed. The LRDG returned to Yugoslavia in February 1945, operating around Istria and Dalmatia, where Germany still held portions of the mainland and certain strategic islands. The Germans had heavily mined the southern Adriatic and were attempting to cover their shipping by moving only by night, close to shore, and heaving to during the day under camouflage nets. The LRDG was tasked to patrol the coast, find the ships and report their locations to the air force for bombing. This it did with success. It remained in Yugoslavia for the rest of the war.
=== Immune system === Inflammation has been suggested to have a role in the pathogenesis of fibromyalgia. People with fibromyalgia tend to have higher levels of inflammatory cytokines IL-6, and IL-8. There are also increased levels of the pro-inflammatory cytokines IL-1 receptor antagonist. Increased levels of pro-inflammatory cytokines may increase sensitivity to pain, and contribute to mood problems. Anti-inflammatory interleukins such as IL-10 have also been associated with fibromyalgia. Neurogenic inflammation has been proposed as a contributing factor to fibromyalgia. A repeated observation shows that autoimmunity triggers, such as traumas and infections, are among the most frequent events preceding the onset of fibromyalgia. A 2024 discussion concluded that the complexity of FM may mean both autoimmune and non-autoimmune mechanisms occur in FM, possibly in different subgroups of FM.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.